Pharmacokinetics, Pharmacodynamics, and Tolerability of Aleglitazar in Patients With Type 2 Diabetes: Results From a Randomized, Placebo-Controlled Clinical Study

Aleglitazar, a new, potent, and balanced dual PPARα/γ agonist for the treatment of type II diabetes

(2009) Agnes Bénardeau et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

Effect of the dual peroxisome proliferator-activated receptor-α/γ agonist aleglitazar on risk of cardiovascular disease in patients with type 2 diabetes (SYNCHRONY): a phase II, randomised, dose-ranging study

(2009) Robert R Henry et al.   LANCET

Intensive Glycemic Control and Cardiovascular Disease Observations From the ACCORD Study: Now What Can a Clinician Possibly Think?

(2008) W. T. Cefalu et al.   DIABETES

Paget's Disease of the Mandible

(2008) Mayank B. Patel et al.   NEW ENGLAND JOURNAL OF MEDICINE

Intensive Glycemic Control in the ACCORD and ADVANCE Trials

(2008) Robert G. Dluhy et al.   NEW ENGLAND JOURNAL OF MEDICINE

Effects of Intensive Glucose Lowering in Type 2 Diabetes

(2008)   NEW ENGLAND JOURNAL OF MEDICINE